• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA creates modernization plan

FDA creates modernization plan

August 23, 2011
CenterWatch Staff

The FDA is prioritizing development of technologies to compare biosimilars to innovator products in its plan to modernize regulatory science.

Technological advances are challenges and opportunities for the FDA and to keep pace the agency has drafted a plan to modernize regulatory science in key areas.

“As new discoveries yield increasingly complex products, this strategic plan ensures that our experts are equipped to make science-based decisions resulting in sound regulatory policy,” said Margaret Hamburg, commissioner at the FDA.

A section of the plan is dedicated to new approaches to improve product manufacturing and quality. In the chapter the FDA says it must collaborate with industry and academia to understand how new technologies affect safety, efficacy and quality.

Development of new analytical technologies is one area of focus. In particular, the FDA wants methods to: compare biosimilars to reference products; and measure physical structure, chemical properties and safety of nanomaterials and complex dosage forms, such as transdermal patches.

Supporting development and evaluation of novel manufacturing methods is another priority area. Continuous manufacturing, the role of excipients and complex dosage forms, and the impact of novel technologies on product failure rates are fields in which the FDA wants to collaborate with industry.

Cutting risk of microbial contamination is the third and final topic in the manufacturing sector. To meet this goal the FDA wants to: develop sensitive, high-throughput methods to detect microbial contaminants; find alternatives to conventional sterilization; and create reference materials.

A subsection of the document focuses on Quality-by-Design (QbD). FDA QbD efforts are now focused on three areas that the agency briefly outlines in its strategy document. The priority areas are: continuous processing, use of process analytical technologies (PAT), and development of statistical approaches to detect changes in process or product quality.

Upcoming Events

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing